$40 billion: Merck rumored to buy Seagen
- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
- HIV infection may shorten a person’s life expectancy by about 5 years
- Moderna CEO: The COVID-19 vaccine will be updated every year like the iPhone 1 dose per year
- UK approved the world’s first vaccine for COVID-19 Omicron
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
$40 billion: Merck rumored to buy Seagen
- A highly infectious disease that has been extinct for more than 40 years has appeared in New York
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Omicron new variant BA.2.75 has stronger infectivity than BA.4 and BA.5?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
$40 billion: Merck rumored to buy Seagen
Merck is in advanced talks to buy Seagen and plans to reach an agreement in the coming weeks to acquire the cancer biotech company in a deal that could total about $40 billion or more, according to a report in the Wall Street Journal, citing people familiar with the matter.
Merck is in advanced talks to buy Seagen and plans to reach an agreement in the coming weeks to acquire the cancer biotech company in a deal that could total about $40 billion or more, according to a report in the Wall Street Journal, citing people familiar with the matter.
The two companies are negotiating a purchase price above $200 a share and are seeking to reach an agreement on or before Merck & Co. reports its second-quarter fiscal 2022 report on July 28, people familiar with the matter said.
As of the close of U.S. stocks on July 7, 2022, Merck’s shares fell slightly by 0.13% to $93.01 per share, and Seagen’s shares rose 1.61% to $177.95 per share.
But it is worth noting that even if the two sides reach an agreement, the final settlement of the transaction still needs to pass the antitrust review of the United States.
As early as June 18, 2022, according to the Wall Street Journal, Merck is considering acquiring Seagen, the leading ADC company.
Merck and Seagen have previously formed a partnership. In September 2020, Merck introduced the LIV-1-targeting antibody-drug conjugate (ADC) ladiratuzumab vedotin, with a total transaction value of $4.5 billion, including a $600 million down payment, a $1 billion equity investment, and a maximum of $2.6 billion in mileage.
At the same time, Merck acquired the rights to commercialize the tyrosine kinase inhibitor tucatinib in Asia, the Middle East and Latin America, and other regions (outside the U.S., Canada and Europe) for $190 million.
Seagen is a leader in the ADC field. Currently, 4 new ADC drugs (3 independent research and 1 cooperative development) have been approved for marketing, and there are many new ADC drugs under development. In 2021, the sales revenue of the listed products for Seagen will be 1.38 billion US dollars.
$40 billion: Merck rumored to buy Seagen
(source:internet, reference only)
Disclaimer of medicaltrend.org
